Mandy M. T. van Leent

Mandy M. T. van Leent

Auto-generated profile, based on publicly available information

Mandy M. T. van Leent

Department of Radiology, BioMedical Engineering and Imaging Institute (A.J.P.T., M.M.T.v.L.), Icahn School of Medicine at Mount Sinai, New York, NY

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Immunity
Verified
Journal Article
Closed access
MBMounia S. Braza
Mounia S. Braza
MLMandy M.T. van Leent
Mandy M.T. van Leent
MLMarnix Lameijer
Marnix Lameijer
BSBrenda L. Sanchez-Gaytan
Brenda L. Sanchez-Gaytan
RARob J.W. Arts
Rob J.W. Arts
JOJordi Ochando
Jordi Ochando

16 April 2018 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
MLMarnix Lameijer
Marnix Lameijer
TBTina Binderup
Tina Binderup
MLMandy M. T. van Leent
Mandy M. T. van Leent
MSMax L. Senders
Max L. Senders
FFFrancois Fay
Francois Fay
RDRaphaël Duivenvoorden
Raphaël Duivenvoorden
Macrophage accumulation in atherosclerosis is directly linked to the destabilization and rupture of plaque, causing acute atherothrombotic events. Circulating monocytes enter the plaque and differentiate into macrophages, where they are activated by CD4+ T lymphocytes through CD40–CD40 ligand signalling. Here, we report the development and multiparametric evaluation of a nanoimmunotherapy that moderates CD40–CD40 ligand signalling in monocytes and macrophages by blocking the interaction between CD40 and tumour necrosis factor receptor-associated factor 6 (TRAF6). We evaluated the biodistribution characteristics of the nanoimmunotherapy in apolipoprotein E-deficient (Apoe–/–) mice and in non-human primates by in vivo positron-emission tomography imaging. In Apoe–/– mice, a 1-week nanoimmunotherapy treatment regimen achieved significant anti-inflammatory effects, which was due to the impaired migration capacity of monocytes, as established by a transcriptome analysis. The rapid reduction of plaque inflammation by the TRAF6-targeted nanoimmunotherapy and its favourable toxicity profiles in both mice and non-human primates highlights the translational potential of this strategy for the treatment of atherosclerosis.

30 October 2024 in Nature
Verified
Journal Article
Closed access
PDF file
PHPacific Huynh
Pacific Huynh
JHJan D. Hoffmann
Jan D. Hoffmann
TGTeresa Gerhardt
Teresa Gerhardt
MKMáté G. Kiss
Máté G. Kiss
FZFaris M. Zuraikat
Faris M. Zuraikat
CMCameron S. McAlpine
Cameron S. McAlpine

7 February 2022 in Nature Reviews Materials
Verified
Journal Article
Closed access
PDF file
MLMandy M. T. van Leent
Mandy M. T. van Leent
BPBram Priem
Bram Priem
DSDavid P. Schrijver
David P. Schrijver
ADAnne de Dreu
Anne de Dreu
SHStijn R. J. Hofstraat
Stijn R. J. Hofstraat
WMWillem J. M. Mulder
Willem J. M. Mulder

10 March 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MLMandy M. T. van Leent
Mandy M. T. van Leent
TBThijs J. Beldman
Thijs J. Beldman
YTYohana C. Toner
Yohana C. Toner
MLMarnix A. Lameijer
Marnix A. Lameijer
NRNils Rother
Nils Rother
RDRaphaël Duivenvoorden
Raphaël Duivenvoorden
Macrophages play a central role in the pathogenesis of atherosclerosis. The inflammatory properties of these cells are dictated by their metabolism, of which the mechanistic target of rapamycin (mTOR) signaling pathway is a key regulator. Using myeloid cell–specific nanobiologics in apolipoprotein E–deficient (Apoe−/−) mice, we found that targeting the mTOR and ribosomal protein S6 kinase-1 (S6K1) signaling pathways rapidly diminished plaque macrophages’ inflammatory activity. By investigating transcriptome modifications, we identified Psap, a gene encoding the lysosomal protein prosaposin, as closely related with mTOR signaling. Subsequent in vitro experiments revealed that Psap inhibition suppressed both glycolysis and oxidative phosphorylation. Transplantation of Psap−/− bone marrow to low-density lipoprotein receptor knockout (Ldlr−/−) mice led to a reduction in atherosclerosis development and plaque inflammation. Last, we confirmed the relationship between PSAP expression and inflammation in human carotid atherosclerotic plaques. Our findings provide mechanistic insights into the development of atherosclerosis and identify prosaposin as a potential therapeutic target.

29 August 2020 in Cells
Verified
Journal Article
Open access
PDF file
KPKikkie Poels
Kikkie Poels
MLMandy M. T. van Leent
Mandy M. T. van Leent
MRMyrthe E. Reiche
Myrthe E. Reiche
PKPascal J. H. Kusters
Pascal J. H. Kusters
SHStephan Huveneers
Stephan Huveneers
TSTom T.P. Seijkens
Tom T.P. Seijkens
T cell-driven inflammation plays a critical role in the initiation and progression of atherosclerosis. The co-inhibitory protein Cytotoxic T-Lymphocyte Associated protein (CTLA) 4 is an important negative regulator of T cell activation. Here, we studied the effects of the antibody-mediated inhibition of CTLA4 on experimental atherosclerosis by treating 6–8-week-old Ldlr−/− mice, fed a 0.15% cholesterol diet for six weeks, biweekly with 200 μg of CTLA4 antibodies or isotype control for six weeks. 18F-fluorodeoxyglucose Positron Emission Tomography—Computed Tomography showed no effect of the CTLA4 inhibition of activity in the aorta, spleen, and bone marrow, indicating that monocyte/macrophage-driven inflammation was unaffected. Correspondingly, flow cytometry demonstrated that the antibody-mediated inhibition of CTLA4 did not affect the monocyte populations in the spleen. αCTLA4 treatment induced an activated T cell profile, characterized by a decrease in naïve CD44−CD62L+CD4+ T cells and an increase in CD44+CD62L− CD4+ and CD8+ T cells in the blood and lymphoid organs. Furthermore, αCTLA4 treatment induced endothelial activation, characterized by increased ICAM1 expression in the aortic endothelium. In the aortic arch, which mainly contained early atherosclerotic lesions at this time point, αCTLA4 treatment induced a 2.0-fold increase in the plaque area. These plaques had a more advanced morphological phenotype and an increased T cell/macrophage ratio, whereas the smooth muscle cell and collagen content decreased. In the aortic root, a site that contained more advanced plaques, αCTLA4 treatment increased the plaque T cell content. The short-term antibody-mediated inhibition of CTLA4 thus accelerated the progression of atherosclerosis by inducing a predominantly T cell-driven inflammation, and resulted in the formation of plaques with larger necrotic cores and less collagen. This indicates that existing therapies that are based on αCTLA4 antibodies may promote CVD development in patients.